Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29913938 | 1.00 | EPHX2 (0.60) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL119223 | 1.00 | EPHX2 (0.60) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL3209124 | 0.92 | EPHX2 (0.55) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL29342668 | 0.90 | EPHX2 (0.57) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL569859 | 0.89 | EPHX2 (0.54) | EPHX2KMT2ACASP3NPC1RAB9A | |
| SCHEMBL8088703 | 0.88 | EPHX2 (0.56) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL15186922 | 0.87 | EPHX2 (0.61) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL3203815 | 0.87 | EPHX2 (0.65) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL6346117 | 0.87 | EPHX2 (0.52) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL1157612 | 0.86 | EPHX2 (0.57) | EPHX2KMT2AFABP7FABP5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400614-A1 | CLEAVABLE PEPTIDES AND METHODS OF USE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-12-05 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024150172-A1 | CLEAVABLE PEPTIDES AND METHODS OF USE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400614-A1 | CLEAVABLE PEPTIDES AND METHODS OF USE THEREOF | DNPEP, TMPRSS15, CPB1 | EPHX2 2908/4885KMT2A 3925/4885FABP7 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.